Enfusion Stock To Remain Range-Bound In 2024 Amid Stable Hedge Fund Market: Goldman Sachs Analyst Downgrades Stock
15
0
Goldman Sachs analyst Gabriela Borges downgraded Enfusion Inc (NYSE:ENFN) from Neutral to Sell and lowered the price target from $9 to $8.
While the stock has already underperformed the NASDAQ by 54% over the last 12 months, the analyst expects the stock to be range-bound in 2024.
Street estimates reflect 10 points of acceleration in revenue over the next 12 months, and Borges is more conservative with her modeling assumptions at 3 points. The analyst is 5% below the Street on revenue for 2025.
Her industry conversations suggest that the outlook for hedge funds is stable (rather than improving or deteriorating) — and against …
Full story available on Benzinga.com
Visited 15 times, 1 visit(s) today
